Citi analyst Yigal Nochomovitz raised the firm’s price target on Zymeworks (ZYME) to $19 from $18 and keeps a Buy rating on the shares.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks: Promising Pipeline and Financial Stability Justify Buy Rating
- Zymeworks Faces Challenges in Diagnostic Test Development Amidst Regulatory Changes
- Zymeworks’ Earnings Call: Achievements and Challenges
- Zymeworks: Hold Rating Amid Limited Near-Term Catalysts and Strategic Resource Allocation
- Zymeworks Reports 2024 Financial Results and Pipeline Progress
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue